Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Choose from credit cards with zero annual fees that offer cash back rewards. Keep all your rewards and maximize your savings.
23,592 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A political clash at the Milan Cortina Games after Trump described a U.S. Olympian as a 'real Loser' has ignited a de...
The US dollar still dominates oil trades, but signals of strain are rising. Tensions in the Middle East and a push to...
Ethereum approaches a decisive breakout, slipping about 4% to the $2,380s. Analysts highlight a binary setup: a drop ...
A targeted Florida housing bill aims to convert idle Southeast Florida golf courses into housing, triggering lawsuits...
Howard Lindzon’s work with StockTwits and Social Leverage reshapes how we think about investing in communities. This ...
American Express is scrapping its long-standing unit-by-unit bonus race. The company now ties executive pay to overal...
PropLogix launches PropOptix, a sales outreach platform that uses real-time market signals to connect title firms wit...
The Roundhill Memory ETF fell roughly 5% in early trading after a dramatic six-week breakout. Analysts say profit-tak...
Market chatter centers on Caterpillar as a top pick amid rising oil demand, renewed infrastructure spending, and a su...
U.S. spot Bitcoin ETFs posted seven consecutive weeks of inflows, the longest streak in months, as institutional appe...
Cisco shattered expectations with a record Q3 revenue print and elevated AI infrastructure guidance, triggering a cho...